Altasciences Featured Articles

31. Cancer Therapeutic Drug Developer Minimizes Production Losses 1/8/2024

    Follow the journey of a prominent cancer therapeutics developer who faced persistent manufacturing challenges with liquid-filled capsules, and how they overcame product and monetary losses.

32. Benefits Of Liquid-Filled Capsules In Pharmaceutical Development 1/8/2024

    Often selected for drugs with poor solubility/bioavailability, liquid-filled hard-shell capsules (LFHCs) stand as a versatile solution and have applications in a number of other situations.

33. Critical Considerations for the Manufacturing of Highly Potent Drugs 1/8/2024

    Examine the intricacies of manufacturing highly potent APIs and associated drug products to ensure compliance with GMP regulations.

34. Expert Insights On End-To-End Central Nervous System (CNS) Drug Development 1/5/2024

    Altasciences' premier CNS Center of Excellence can help you seamlessly navigate early-phase drug development with expert solutions, saving up to 40% in time along the way.

35. Applications Of Liquid-Filled Hard-Shell Capsules In Drug Development 1/5/2024

    Explore the versatility and significance of LFHCs in pharmaceutical and nutraceutical delivery, as well as their role in enhancing drug solubility, bioavailability, and overall efficiency.

36. Overcoming Solubility Challenges With Nanomilling 1/5/2024

    Explore why this highly complex process requires a unique level of CDMO expertise that can only be gained through extensive experience with developing a broad range of APIs.

37. Terminal Sterilization Of Pharmaceutical Products 1/5/2024

    Learn why adherence to sterile conditions is an essential step in drug development and manufacturing to guarantee the safety, efficacy, quality, and regulatory compliance of pharmaceutical products.

38. Maximizing Drug Formulations For First-In-Human Trials 1/5/2024

    Discover the importance of drug product formulation and manufacture for FIH trials, and how they can determine if the correct dosage is safely provided and, ultimately, gain regulatory approval.

39. One Integrated Solution For Meeting Early Drug Development Needs 1/26/2023

    Over 143 executives of biopharmaceutical companies provided insights in a survey to understand the challenges they face when outsourcing their early phase drug development programs.

40. Ophthalmic End-To-End Drug Development Solutions 1/26/2023

    Overcome challenges and complexities in ophthalmic drug development by partnering with an integrated CRO/CDMO provider with extensive regulatory knowledge and scientific expertise.